Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody.

@article{Schroeder2015ProteolyticCO,
  title={Proteolytic cleavage of antigen extends the durability of an anti-PCSK9 monoclonal antibody.},
  author={Krista M. Schroeder and Thomas P. Beyer and Ryan J. Hansen and Bomie Han and Richard T. Pickard and Victor J Wroblewski and Mark C. Kowala and Patrick I. Eacho},
  journal={Journal of lipid research},
  year={2015},
  volume={56 11},
  pages={2124-32}
}
Lilly PCSK9 antibody LY3015014 (LY) is a monoclonal antibody (mAb) that neutralizes proprotein convertase subtilisin-kexin type 9 (PCSK9). LY decreases LDL cholesterol in monkeys and, unlike other PCSK9 mAbs, does not cause an accumulation of intact PCSK9 in serum. Comparing the epitope of LY with other clinically tested PCSK9 mAbs, it was noted that the LY epitope excludes the furin cleavage site in PCSK9, whereas other mAbs span this site. In vitro exposure of PCSK9 to furin resulted in… CONTINUE READING

From This Paper

Topics from this paper.

Citations

Publications citing this paper.
Showing 1-9 of 9 extracted citations

New approaches to address dyslipidemia.

Current opinion in lipidology • 2017
View 1 Excerpt

Similar Papers

Loading similar papers…